Integrative bioinformatics approach yields a novel gene expression risk model for prognosis and progression prediction in prostate cancer

Abstract

AbstractProstate cancer (PCa), a prevalent malignancy among elderly males, exhibits a notable rate of advancement, even when subjected to conventional androgen deprivation therapy or chemotherapy. An effective progression prediction model would prove invaluable in identifying patients with a higher progression risk. Using bioinformatics strategies, we integrated diverse data sets of PCa to construct a novel risk model predicated on gene expression and progression‐free survival (PFS). The accuracy of the model was assessed through validation using an independent data set. Eight genes were discerned as independent prognostic factors and included in the prediction model. Patients assigned to the high‐risk cohort demonstrated a diminished PFS, and the areas under the curve of our model in the validation set for 1‐year, 3‐year, and 5‐year PFS were 0.9325, 0.9041 and 0.9070, respectively. Additionally, through the application of single‐cell RNA sequencing to two castration‐related prostate cancer (CRPC) samples and two hormone‐related prostate cancer (HSPC) samples, we discovered that luminal cells within CRPC exhibited an elevated risk score. Subsequent molecular biology experiments corroborated our findings, illustrating heightened SYK expression levels within tumour tissues and its contribution to cancer cell migration. We found that the knockdown of SYK could inhibit migration in PCa cells. Our progression‐related risk model demonstrated the potential prognostic value of SYK and indicated its potential as a target for future diagnosis and treatment strategies in PCa management.